Depression Clinical Trials in Houston

Showing 21-40 of 197 trials

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698

This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.

SchizophreniaSchizoaffective DisorderBipolar Disorder+2 more

Neurocrine Biosciences59 participantsStarted May 2023

Bryant, Arkansas, United States • Anaheim, California, United States • Orange, California, United States +15 more locations

Not Yet RecruitingPhase 2< 1 mile

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

NCT06705478

A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes. An optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants.

Major Depressive DisorderMild Neurocognitive DisorderHIV

National Institute of Allergy and Infectious Diseases (NIAID)186 participantsStarted Feb 2026

Birmingham, Alabama, United States • Los Angeles, California, United States • San Diego, California, United States +37 more locations

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Depression Trials in Other Cities

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan

DBS of the Lateral Habenula in Treatment-Resistant Depression

Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression

Multisite RCT of STEP-Home: A Transdiagnostic Skill-based Community Reintegration Workshop

Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing

Neonatal Neurodevelopmental Outcomes

A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE')

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

Mobile Health and COVID-19

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms

A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Other Conditions in Houston